Organisation paid for research Program year 2025 Source: CMS Open Payments

PPD

Neither a doctor nor a teaching hospital

Research payments

$9,225,526

83 payments

Through program year 2025, PPD is reported as receiving $9,225,526 in research payments, across 83 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$268,634	6
2024	Research	$511,841	8
2023	Research	$387,697	2
2022	Research	$4,538,171	34
2021	Research	$1,432,286	4
2020	Research	$1,976,649	26
2019	Research	$110,249	3

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $5,082,420 46 payments
ViiV Healthcare Company $4,116,361 34 payments
H. Lundbeck A S $25,776 2 payments
Eli Lilly and Company $969 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the PH $1,904,304 21 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $1,733,278 4 payments
Open-Label, Single-Sequence Study to Evaluate the Effects of Darunavir $952,495 10 payments
Effects of Gsk3640254 on the Single-Dose Pharmacokinetics of Probe Sub $792,285 3 payments
A Phase 1, Two-Part, Double-Blind, Active Control, Randomized Study to $737,875 4 payments
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel GR $550,934 10 payments
A Phase 1, Two-Part, Double-Blind, Active-Control, Randomized Study to $507,990 3 payments
A Study to Evaluate the Effect of Therapeutic and Supratherapeutic Ora $399,216 3 payments
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Stu $386,728 1 payment
A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical St $336,282 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.